Login to Your Account



KaloBios Adds $35M in Debt, Equity for Asthma, CF Trials

By Catherine Shaffer
Staff Writer

Monday, September 10, 2012
Debt financing of up to $15 million, plus a Series E preferred stock financing closed in the second quarter, will help KaloBios Pharmaceuticals Inc., of South San Francisco, advance its monoclonal antibody therapeutics through Phase II trials in asthma and cystic fibrosis, as well as fund a Phase I trial in cancer.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription